Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class ...

Sitryx CEO Iain Kilty describes the biopharmaceutical industry effort to go beyond immunosuppression in autoimmune and ...

SYX-5219 offers first-in-class potential as an oral, disease-modifying anti-inflammatory therapy, targeting a critical enzyme that regulates cell metabolism called pyruvate kinase M2 (PKM2).

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission Novel mechanism of action suggests SYX-5219 has potential across broad range of inflammatory diseases ...

Background and objective Colon Cancer (CC) is a common malignant tumor. The aim of this study was to investigate the role and regulatory mechanism of circular RNA pappalysin-1 (circ-PAPPA; ...

Department of Rheumatology and Immunology, Changhai Hospital, Naval Medical University, Shanghai 200433, China ...